Home
Storia in 1 fonti
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Neurogene today and set a price target of $60.00.Claim 55% Off TipRanksUnlock...
Raccontata da
markets.businessinsider.com
Timeline cronologica
- ·
LifeSci Capital Remains a Buy on Ibio (IBIO)
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00.Claim 55% Off Tip...
- ·
LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.Claim 55% Off Ti...
- ·
LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Neurogene today and set a price target of $60.00.Claim 55% Off TipRanksUnlock...